Open AccessIn vivo treatment with anti B‐220 monoclonal antibody affects T and B cell differentiation
Author(s) -
ASENSI V.,
HIMENO K.,
KAWAMURA I.,
SAKUMOTO M.,
NOMOTO K.
Publication year - 1990
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1990.tb05246.x
Subject(s) - phytohaemagglutinin , monoclonal antibody , immunology , microbiology and biotechnology , biology , cytotoxic t cell , antigen , splenocyte , b cell , concanavalin a , t cell , in vivo , antibody , t lymphocyte , lymphocyte , immune system , in vitro , biochemistry
SUMMARY The B220 cell marker is expressed on B cells and on T cell precursors. In order to determine the involvement of the B220 antigen on murine lymphoid differentiation, we treated 5‐10‐week‐old mice periodically with a specific anti‐B220 antibody, RA3‐6B2, a non‐cytolytic IgG2b. After the third injection, a significant reduction (P < 0·02) in the number of thymocytes and less dramatically in the number of splenocytes was observed. This reduction was predominantly due to a decrease of cells carrying the following markers: Thy‐1.2 + , Lyt‐1 + , Lyt‐2.3 + , L3T4 + , and asGMl + . Mitogenic response to concanavalin A, phytohaemagglutinin and lipopolysaccharide, mixed lymphocyte reaction, cytotoxic T cell activity, and plaque‐forming cell generation were significantly decreased after the treatment (P < 0·01). These results show that the in vivo treatment with anti‐B220 monoclonal antibody reduced the number of T and B cells and modified their functional activity. This suggests that the B220 antigen is involved in the maturation of both T and B cells.